Targeting ‘undruggable’ proteins promises new approach for treating neurodegenerative diseases

Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s are challenging to treat due to the complexity of the brain and the lack of effective therapies. However, a promising new approach involves targeting ‘undruggable’ proteins that play a key role in these diseases.

Traditionally, drug discovery has focused on targeting proteins that have well-defined binding sites for small molecules. However, many proteins that are implicated in neurodegenerative diseases do not have such easily targetable sites, earning them the label of ‘undruggable’.

Recent advancements in technology, such as proteolysis-targeting chimeras (PROTACs) and small molecule-induced protein degradation, have opened up new possibilities for targeting these previously inaccessible proteins. By inducing the degradation of ‘undruggable’ proteins, researchers can effectively neutralize their harmful effects and potentially treat neurodegenerative diseases at their root cause.

One example of this approach is the targeting of tau protein in Alzheimer’s disease. Tau is a microtubule-associated protein that forms tangles in the brains of Alzheimer’s patients, leading to neuronal damage and cognitive decline. While tau has been considered ‘undruggable’ in the past, recent studies have shown that PROTACs can target tau for degradation, offering a potential new avenue for Alzheimer’s treatment.

Overall, targeting ‘undruggable’ proteins represents a promising new frontier in the treatment of neurodegenerative diseases. By harnessing innovative technologies and approaches, researchers are paving the way for more effective and targeted therapies that could significantly impact the lives of patients suffering from these devastating conditions.